# EDGAR Filing Document

**Accession Number:** 0001850119
**File Stem:** 0001104659-23-002039
**Filing Date:** 2023-1
**Character Count:** 36134
**Document Hash:** 24822359f13f340781a0daf194ee2642
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-002039.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0001104659-23-002039

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20230105

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Century Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001850119
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 842040295
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40498
- **FILM NUMBER:** 23516493

**BUSINESS ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104
- **BUSINESS PHONE:** 215-981-4000

**MAIL ADDRESS:**
- **STREET 1:** 3675 MARKET STREET
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 5, 2023**

------

**Century Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40498** | **84-2040295** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **3675 Market Street**<br> **Philadelphia, Pennsylvania**  | **19104** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(267) 817-5790**

**Not Applicable**

(Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Exchange on Which<br> Registered** |
| **Common Stock, par value $0.0001 per share** | **IPSC** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 7.01** | **<u>Regulation FD Disclosure</u>** |

---

On January 9, 2022, Century Therapeutics, Inc. (the "Company") updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 8.01** | **<u>Other Events</u>** |

---

On January 5, 2023, the Company issued a press release announcing its plan for internal portfolio prioritization to extend its cash runway into 2026. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **<u>Financial Statements and Exhibits</u>** |

---

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Document** |
| [99.1](tm232470d1_ex99-1.htm) | [Investor Presentation of Century Therapeutics, Inc., dated January 9, 2022](tm232470d1_ex99-1.htm) |
| [99.2](tm232470d1_ex99-2.htm) | [Press Release of Century Therapeutics, Inc., dated January 5, 2023](tm232470d1_ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **CENTURY THERAPEUTICS, INC.** | **CENTURY THERAPEUTICS, INC.** |
| By: | /s/ Osvaldo Flores, Ph.D. |
| Name: | Osvaldo Flores, Ph.D. |
| Title: | President and Chief Executive Officer |

---

Date: January 9, 2023

## Exhibit 99.1

#### Exhibit 99.1

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img001.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate OverviewJanuary 2023  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img002.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 Forward-looking statementsThis presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates throughdevelopment activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and laborforce; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img003.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 Investment Thesis Next generation platforms for iNKand gamma delta iTcandidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno-oncology, manufacturing and commercializationExemplified by FDA clearance of Century's first IND for CNTY-101 Well capitalized with cash runway into 2026 Operational efficiencies designed to enable delivery on key milestones, clinical data  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img004.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 Finding operational efficiencies to extend the cash runwayPortfolio Prioritization Operational efficiencies•Prioritization of key pipeline assets enabled by de-prioritizing further investment in CNTY-103•CNTY-107 (Nectin-4+ tumors), CNTY-102 (lymphomas) have BIC potential•Not overinvesting in any disease area •Realizing further synergies across the organization•Streamlining R&D lab operations in Philadelphia•While executing on key milestones Cash runway extended into 2026 following portfolio reprioritization  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img005.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iPSC Platform  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img006.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 Building a next generation allogeneic cell therapy platform Gene Editing•Proprietary gene editing platform•CRISPR MAD7-derived gene editing for precise transgene integrationProtein Engineering•Developing proprietary next-generation CARs•Universal tumor targeting platformiPSC Differentiation/Manufacturing•Scalable protocols and processes to produce highly functional iNKand iTcell productsiPSC Reprogramming•Comprehensive collection of clinical grade lines (CD34+ HSC, αβT cell, γδT cell derived) Vertically integrated capabilities differentiate Century's approach  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img007.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 Foundational investments in iPSC know-how and manufacturing Established in-house manufacturing accelerates learnings and enables faster product iteration•53,000 ft2facility •Designed to produce multiple immune cell types•Two sites provides optionality and maximizes flexibilityiPSC license and collaboration agreement established in 2018•Access to clinical grade iPSC lines •Exclusive IP and know-how to generate immune effector cells using feeder-free methods (NK, T, Mac, DC)•FCDI GMP manufacturing capacity for Century's product candidates•Leveraging two decades of research & investment at University of Wisconsin and FCDI  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img008.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 Multiple gene edits (KO/KI)iPSC bank Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Engineered iPSC Master Cell Bank(MCB) Advantages of Century's PlatformPreciseCRISPR mediated homology directed repair reduces off-target integrationStepwise and efficient gene editing avoids risky multiplex modificationand structural variantsQuality control through generation of homogenous MCB establishes genomic product integrityManufacturing begins at the MCB, confirmed to be free from genetic aberrations Sequential selection steps iSPCPrecision EngineeringCRISPR-mediated HDR (MAD 7)  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img009.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 Potential to drive durable responses with engineering to resist immune rejectionAllo-EvasionTMedits + repeat dosing = potential greater durability Next-wave of allogeneic cell therapies must solve for challenge of rejection  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img010.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 Allo-EvasionTM1.0 designed to overcome 3 major pathways of host vs graft rejection1.Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2.Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells3.Knock-in of HLA-E prevents killing by NK cells β 2M KO (HLA-I) HLA-E KICIITA KO (HLA-II) CD8+ T Cell CD4+T Cell NK cell 3 core edits disarm host cells from eliminating therapy  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img011.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 Allo-EvasionTM3.0 Provides Additional Protection Against NK Cell Killing1.Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2.Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells3.Knock-in of HLA-E prevents killing by NK cells4.Knock-in of HLA-G prevents killing by NK cells β 2M KO (HLA-I) HLA-E KICIITA KO (HLA-II) CD8+ T Cell CD4+T Cell NK cell 4 core edits disarm host cells from eliminating therapy HLA-G KI  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img012.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 Expression of HLA-E + HLA-G further protects from NK cell killing HLA-EHLA-GNKG2AKIRs, LIRsActivating ligandActivating receptorProof-of-Concept Study with HLA-I Null K562 Cells Engineered with HLA-E and HLA-G 0.1250.250.512481632 02040 60 80100 Donor RC01Ratio (E:T)% KillingParental K562 HLA-G K562 HLA-E K562 HLA-E+G K562 Te Coination o HLA-E + HLA-G roved Protection to Killing y Allogeneic NK Cells•HLA-E and HLA-G engage different receptors on NK cells including NKG2A, KIRs, and LIRs•The expression of NKG2A, KIRs, and LIRs varies among NK cells from different donorsAgglomerated Data from 22 NK Cell Donors No editHLA-GHLA-EHLA-E/G 0.00.20.40.60.81.0 Relative cytolysis  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img013.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discovery  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img014.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 Common progenitor milestone enables cost, time efficiencies Multiple gene editsEngineered iPSC iNK celliPSC bank Cell engineeringManufacturingCommon ProgenitoriNK3.0 CD34+HSC T cell Reprogramming Reprogramming DifferentiationNK cell •iPSC cell bank with 12 core 3.0 gene edits introduced in 5 sequential steps•Resetsproduct development starting point: accelerates and de-risks development candidate selection New Starting Point+ CAR  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img015.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 iNKcommon progenitor edits confer improved persistence and anti-tumor efficacy Engineering with IL15/IL15Ra shows increased persistence in vitro and in vivoHigh affinity CD16 demonstrates enhanced ADCC activityGurung, et al, SITC 2022 iNKcells engineered with NKG2D demonstrate enhanced tumor cell killing  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img016.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pipeline and Franchises  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img017.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17 ProductiPSC PlatformTargetsIndicationsDiscoveryPreclinicalClinicalCollaboratorCNTY-101iNKCD19B-Cell MalignanciesCNTY-102iT CD19 + CD79bB-Cell MalignanciesCNTY-107iTNectin-4Solid TumorsPrograms in Collaboration CNTY-104iNK/iTMulti-specificAcute Myeloid LeukemiaCNTY-106iNK/iTMulti-specificMultiple MyelomaResearch ProgramsDiscoveryiNK/iTTBDHematological / Solid TumorsUpdated pipelineProduct candidate pipeline across cell platforms and targets in solid and hematologic cancers Hematologic TumorsSolid Tumors  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img018.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18 Promise of allogeneic cell therapies in lymphoma intact Large unmet need remains despite progress with autologous cell therapies•~25% of eligible patients receive CAR-T therapy1•~35% of patients achieve long- term remission even in earlier lines of therapy1Off-the-shelf modalities approaching bar set by autologous but falling short on durability •Rejection limits potential of durable responses for first wave of allogeneic cell products•Bispecifics lack curative potential of cell therapyGoal to deliver more durable response rates vs autologous X •CNTY-101 is designed to protect cell product from rejection (Allo-EvasionTM)•Shift from "one and done" to finite repeat dosing to increase pharmacological pressure1. Targeted Oncology, Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma, Sept 2022  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img019.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19 Differentiating features:First cell therapy product candidate designed to avoid all major pathways of host vs graft rejection to realize potential of repeat dosingPotential to exceed bar set by autologous and deliver durable responses Vision to eliminate need for lymphodepletion with subsequent cycles to increase tolerability and ease of outpatient administration CNTY-101: Differentiated next-gen CD19 targeted productCNTY-101Allo-EvasionTMedits HLA-I KnockoutIL-15 HLA-IIKnockoutCD19 CARHLA-E Safety Switch Currently enrolling patients with relapsed/refractory CD19+ B-cell malignancies  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img020.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 CNTY-101 shows strong pre-clinical anti-tumor activity In Vitro Serial killing assay Robust activity against lymphoma xenograftBorges, et al, ASH2021  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img021.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 ELiPSE-1: First-in-Human Study CNTY-101Study will assess:Impact of Allo-EvasionTMon iNK cell persistence and PK after multiple dosing (Schedule B)Multiple dose regimen with up to 6 doses with single lymphodepletion conditioningPotential to increase durability of responses with Allo-EvasionTMenabled repeat dosing regimen Day 1 LDDay 50 Subsequent dose(s) without additional LD\* ≥1bn cells/dose\* Subject to FDA approvalSchedule A: Single ascending dose study (3+3 escalation design) DL1DL2DL3100M300M1BnSchedule B: Accessing multiple doses per cycle+ IL-22ndcycle of single dose allowed for patients who demonstrate benefit  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img022.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22 Winning in Solid Tumors Trafficking and infiltration γδiTcells - tissue homing TME / Immunosuppressive environment Requirement for chemotherapy conditioning Tumor heterogeneity •Novel conditioning regimens•Genetic engineeringChallengesCentury's Solution Future engineering strategies •Engage endogenous immunity•Multi tumor targeting pathways CARCD16TCRCytokine supportAllo-Evasion TMEnhanced fitnessTracer TBD  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img023.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 iPSC-derived GD T cells effective at tumor control as monotherapy and in combination with antibody Millar, et al, SITC 2022γδ-EGFR-CAR-T cells demonstrate significant CAR killing of ovarian spheroids γδCAR-T demonstrate additive efficacy in combination with trastuzumab Treatment% TGISignificance trastuzumab0P=0.9980γδ-CAR-T18P=0.7073γδ-CAR-T + trastuzumab42P=0.0358TGI = Tumor Growth Inhibition  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img024.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 CNTY-107: First in Class Nectin-4 Targeted GD iTCell TherapyNectin-4 has been validated by ADC approaches•Opportunity to address multiple Nectin-4 positive solid tumors•Potential indications include bladder, breast, pancreatic, non-small cell lung cancer, esophageal/gastric, head and neck, and/or ovarian cancers1GD iTallogeneic therapies provide potential to improve upon ADC toxicity profile and efficacy•Intrinsic homing of GD iTcells to tissues and solid malignancies•Multi-tumor killing modalities to tackle heterogeneity Tumor cell killingAllo-EvasionTM Cell FitnessCNTY-107 Illustrative construct Nectin-4 CARCD16Tracer TCR Cytokine support 1. Cancer Res . 2016 May 15;76(10):3003-13  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img025.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 Strategy and 3-year vision for growthDelivering on potential for allogeneic cell therapies by exceeding efficacy, safety and logistics of autologous approaches2026+Advancing multiple development candidatesClinical trial execution (ELiPSE-1) CNTY-102 development candidate pre-clinical data Multiple clinical stage candidatesCNTY-101 clinical data providing initial proof of conceptPoised for pivotal start in lymphomaInitial clinical data with gamma delta T cell programs: CNTY-107 in Nectin-4 + tumors and CNTY-102 in lymphoma 2023Execution2024Acceleration2025Validation Estimated cash runway to fund operations into 2026  |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;![GRAPHIC](tm232470d1_ex99-1img026.jpg) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging leader in cell therapies for cancerComprehensive iPSC cell platformFor immune effector cellsTechnical ExpertiseGenetic and protein engineering, process development and immuno-oncologyFoundation in ScienceContinuing investment in innovation drives R&DState-of-the-art GMP manufacturing facilityFully operational, enabling improved and faster product iteration Financial StrengthCash runway into 2026, Ended 3Q22 with cash, cash equivalents, and investments of $395.3M~165Employees including experienced leadersand entrepreneursEmerging pipeline of candidatesProduct engine anticipated to deliver multiple INDs over the next 3 yearsBMS Discovery CollaborationInitial focus on AML(CNTY-104) and MultipleMyeloma (CNTY-106)  |

---

## Exhibit 99.2

**Exhibit 99.2**

![](tm232470d1_ex99-2img001.jpg)

**Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026**

January 5, 2023

*- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma -*

- *Employee headcount reduced by approximately 25 percent, extending cash runway into 2026 -* 

 

- *Phase 1 study of CNTY-101, Company's lead candidate targeting CD19, in relapsed/refractory B-cell lymphoma remains on track; No impact to partnered programs with Bristol Myers Squibb -*

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- <u>Century Therapeutics</u> (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced a new internal portfolio prioritization and capital allocation strategy that is expected to extend cash runway into 2026. The resulting changes include de-prioritizing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will prioritize key programs, including one follow-on product candidate for lymphoma, CNTY-102, and CNTY-107, a product candidate for Nectin-4+ tumors. In addition, Century will continue its partnered programs with Bristol Myers Squibb with no impact to previous guidance on timelines.

The strategic initiative allows the Company to reduce its headcount by approximately 25 percent, providing an estimated greater than 3-year cash runway to fund operations. These strategic changes will allow the Company to focus on delivering upon key milestones in the development of candidates that the Company believes have a higher probability of technical success and best-in-class potential. As a result of the operational restructuring, lab operations in Seattle and Hamilton will be closed and research activities will be consolidated in Philadelphia.

"As our confidence in the disruptive potential of our technology platform and prioritized pipeline programs continues to increase, we have implemented these cost saving measures to right size the organization and further extend our cash runway to enable achievement of key milestones," said Lalo Flores, Ph.D., Chief Executive Officer, Century Therapeutics. "As a result, we are losing many valued colleagues, which is an incredibly difficult decision, and we would like to thank each of them for their contributions."

Concurrent with today's announcement, the Company also announced that Hy Levitsky, M.D., Ph.D., President of Research and Development, has tendered his resignation, effective January 31, 2023. Dr. Levitsky's leadership responsibilities will be assumed by Luis Borges, Ph.D., Chief Scientific Officer and Adrienne Farid, Ph.D., Chief Operations Officer and Head of Early Development.

"I am pleased to have been part of the Century team during its formative years and I am tremendously proud of the progress the Company has made, leaving it well positioned for future success," said Dr. Levitsky. "I leave Century with continued confidence in the vision for next-generation iPSC-derived cell therapies."

"On behalf of the entire team, I would like to thank Hy Levitsky for his valuable contributions to the Company," Dr. Flores said.

**Strategy Update**

Based on the outcomes of the strategic portfolio prioritization, the Company will focus on the following:

CNTY-101: lead product candidate targeting CD19 for relapsed/refractory B-cell lymphoma

&nbsp;&nbsp;&nbsp;&nbsp;· CNTY-101 is an iPSC-derived chimeric antigen receptor iPSC-derived
NK (CAR-iNK) cell therapy candidate that has been engineered to include core Allo-Evasion™ edits, express a CD19 CAR, soluble IL-15,
and an EGFR safety switch. The first sites for the ELiPSE-1 Phase 1 trial are activated and are currently recruiting patients. The first
patient is expected to be enrolled imminently.

CNTY-102: multi-specific product candidate for relapsed/refractory B-cell lymphoma and other B-cell malignancies

&nbsp;&nbsp;&nbsp;&nbsp;· CNTY-102 is an iPSC-derived CAR gamma delta iT cell therapy
candidate that will simultaneously target CD19 and a second antigen. This product candidate is designed to increase depth and durability
of response by eliminating the effect of CD19 antigen loss that has been observed as a factor limiting treatment durability.

CNTY-107: gamma delta iT product candidate for the treatment of solid tumors expressing Nectin-4

&nbsp;&nbsp;&nbsp;&nbsp;· CNTY-107 is a first-in-class iPSC-derived Nectin-4 CAR gamma
delta T-cell therapy product candidate that will be engineered with multiple features to provide several mechanisms for tumor killing.
As presented at the Company's virtual Research and Development Day on November 11, 2022, the product candidate will include core
Allo-Evasion™ edits and other features to provide cytokine support, enhance tumor cell killing and cell fitness.

The Company continues its strategic research collaboration with Bristol Myers Squibb for CNTY-104 in acute myeloid leukemia and CNTY-106 in multiple myeloma. These programs are not impacted by the restructuring.

**About Century Therapeutics**

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit <u>www.centurytx.com</u>.

**Century Therapeutics Forward-Looking Statement**

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our future IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

**For More Information:**

Company: Elizabeth Krutoholow – <u>investor.relations@centurytx.com</u>

Investors: Melissa Forst/Maghan Meyers – <u>century@argotpartners.com</u>

Media: Joshua R. Mansbach – <u>century@argotpartners.com</u>